

Short Research Article

Gamma Transcranial Alternating Current Stimulation Improves Craving and Cognition in Patients with Alcohol Use Disorder: An Open Label Pilot Study

ABSTRACT

Objective: Alcohol use disorder (AUD) is one of the most common psychiatric disorders worldwide. It often shows a chronic course, and pharmacological treatment is rather ineffective for maintaining abstinence. New non-invasive brain stimulation techniques could help to improve AUD symptoms by rebalancing and synchronizing the disturbed prefrontal brain function and thus reduce craving.

Methods: In this small open label study, six patients suffering from AUD for several years underwent treatment with prefrontal gamma transcranial Alternating Current Stimulation (gamma tACS) for 10 min twice daily respectively 20 min once per day for 10 days.

Results: Scores of the Alcohol Craving Questionnaire decreased in all patients and cognitive functions assessed by word fluency and computer-based n-back test improved.

Conclusions: This new non-invasive brain stimulation technique could be of interest in treating craving symptoms and in maintaining abstinence.

Keywords: Non-invasive brain stimulation, tACS, AUD, major depressive disorder, cognitive impairment

1. INTRODUCTION

World Health Organization estimates more than 280 million people worldwide suffering from alcoholism in 2010 (Global status report on alcohol and health, 2014, 2014). Alcohol use disorder (AUD), which is defined as disruption of control over alcohol use, continued alcohol use, and continued use despite apparent problems, is one of the most common psychiatric disorders, and still undertreated despite effective therapies being available (Grant et al., 2015). There are established and efficacious treatment regimens for acute withdrawal like benzodiazepines, and long-term maintenance of abstinence respectively reduction of craving symptoms like disulfiram, nalmefene, naltrexone, and acamprosate. However,

benzodiazepines are not recommended for long-term use for dependency reasons and medications to maintain abstinence show moderate effect sizes, e.g. naltrexone and acamprosate, and incidentally result in considerable side effects like peripheral neuropathy that lowers patients' compliance (Liang & Olsen, 2014).

Moreover, patients with AUD often carry the burden of stigmatization and social decline, and have relevant psychiatric comorbidities, e.g. depressive symptoms and cognitive impairment (Grant & Harford, 1995) (Bernardin, Maheut-Bosser, & Paille, 2014).

Currently, non-invasive brain stimulation (NIBS) therapies including repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) are widely investigated for the treatment of psychiatric disorders like major depression, schizophrenia, and substance abuse disorders (Lefaucheur et al., 2017). There is some body of evidence that treatment with tDCS could reduce craving and relapses in AUD inpatients (Klauss, Anders, Felipe, Nitsche, & Nakamura-Palacios, 2018) (Boggio et al., 2008). In addition, improvement of mood and depressive symptoms have been observed (da Silva et al., 2013). Also, for repetitive transcranial magnetic stimulation (rTMS), beneficial effects in substance use disorders have been reported (Mostafavi et al., 2020). Although there is a solid background of evidence for the application of tDCS in psychiatric disorders (Lefaucheur et al., 2017), data for the use of tACS, another NIBS method distinct from tDCS, is almost lacking, as shown in a recent review article with 13 studies included in the synthesis (Elyamany et al., 2021), albeit tACS is investigated in neurophysiological and neuropsychological studies for two decades. However, due to its specific electrical characteristics, tACS could be useful in psychiatric disorders and could be even superior to tDCS. Contrarily to the unidirectional deflection of the resting membrane potential during tDCS, the rapidly changing polarity during tACS application probably prevents neurons from counter-regulation against deflection of neural activity and resting membrane potentials (Tavakoli & Yun, 2017; Antal & Paulus, 2013).

Thus, contrarily to the static electric field of direct current (DC) application with unidirectional current flow, alternating current uses sinusoidal oscillating currents in various frequencies with phase shifts. Changes in neural function or induction of neuroplasticity are supposed to be generated by entrainment or inference of tACS frequencies with local neural or cortical network activity (Tavakoli & Yun, 2017). The underlying mechanism for sustained changes is long term potentiation (LTP) with supra-threshold activation of neurons, followed by signal propagation into interconnected and remote areas (Lee & Silva, 2009). It is suggested that tACS has differential effects on reaction time, attention, and cognition, depending on area of stimulation, frequency, phase shift, and duration of stimulation (Klink et al., 2020; Tavakoli & Yun, 2017). Most clinical and neurophysiological studies investigated alpha and beta frequencies to modulate either psychiatric disorders (Elyamany et al., 2021), or cognitive and perception tasks (Klink et al., 2020). However, there is some neurophysiological evidence that gamma frequency could be a biomarker for psychiatric disorders, e.g. major depression (Fitzgerald & Watson, 2018), and that substance use disorders are linked to changes of cortical gamma frequency (Ramlakhan et al., 2021). Thus, tACS in gamma frequency could be used to modulate symptoms of substance use disorders. Recent studies showed that tACS at 40 Hz (gamma frequency) leads to an improvement of memory performance in healthy volunteers (Zaehle, Rach, & Herrmann, 2010), to mood and cognitive improvement in patients with major depression (Alexander et al., 2019; Haller, Senner, et al., 2020), and to improvement of negative symptoms in patients with negative symptoms in schizophrenia (Haller, Hasan, et al., 2020). However, meaning of gamma tACS for the improvement of cognition is still unclear as recent results on cognition in healthy volunteers and depressed patients are diverging (Palm et al., 2022). It is hypothesized that the neuromodulatory effects of tACS may involve synchronization in frontal and prefrontal brain regions, however, its

mechanisms of action are still unclear (Alexander et al., 2019). In alcohol-dependent persons or persons at high risk, frontal and parietal gamma activity was found to be reduced during cognitive tasks (Padmanabhapillai et al., 2006; Porjesz & Begleiter, 2003). This reduced gamma power leads to altered brain connectivity in persons with chronic alcohol consumption and is likely to attribute to the impaired cognitive function in severe AUD (Ramlakhan et al., 2021), whereas during alcohol withdrawal, gamma activity was found to be increased, pointing to a hyperexcitability (Ahveninen et al., 2000). Therefore, tACS entrainment or interference with endogenous EEG oscillations could also be used to modulate disturbed cognitive function by rebalancing disturbed EEG patterns (Vosskuhl et al., 2018). For the use of gamma tACS in AUD, there is one study comparing different stimulation modes in a population of people with different substance abuse disorders. Compared to alpha tACS, single session gamma tACS did not evoke relevant improvements in a go-no-go-task (Daughters et al., 2020), but it is likely that single session tACS might not have been sufficient to provoke sustained results. Thus, a dosage-effect relationship could be responsible for negative results as also shown by Palm et al. (2022). Clinical NIBS application to provoke sustained changes in psychopathology and clinical symptoms usually requires 1-2 weeks of repeated stimulation, i.e., at least 5-10 stimulations. Therefore, a negative result from a single NIBS session in a neurophysiological or neuropsychological trial is not predictive for a clinical null result. Considering the potential meaning of modulation of gamma oscillations in substance abuse disorders, the investigation of repeated gamma tACS in substance abuse disorder seems promising. Here we provide first clinical data on the use of a gamma tACS stimulation series in patients with AUD. In this study, two different stimulation protocols (20 min once per day versus 10 min twice per day) were used. 20 min stimulation is a widely used duration in tDCS studies (Lefaucheur et al., 2017) and was applied in tACS studies on cognition (Klink et al., 2020; Palm et al., 2022), and in neurophysiological (Kasten et al., 2016) and clinical application (Mellin et al., 2018). Stimulation of 10 min duration is following findings on the improvement of prefrontal control over addiction behavior after prefrontal 10 Hz tACS (McKim et al., 2021), and a variety of neurophysiological (Chaieb et al., 2011; Wach et al., 2013; Wang et al., 2021) and neuropsychological studies (Ambrus et al., 2016; Harada et al., 2020; Klink et al., 2020), however with different frequencies. The application of twice-daily stimulation has brought beneficial effects in clinical tDCS application and was found to accelerate clinical improvement (Jafari et al., 2021; Moirand et al., 2022). Furthermore, there is evidence of a differential outcome of neurophysiological aftereffects after repeated and spaced tDCS, suggesting an enhancing effect of a second stimulation within the neuroplasticity window opened by the first stimulation (Fricke et al., 2011; Monte-Silva et al., 2013).

2. MATERIAL AND METHODS

2.1. General Procedures

The study was approved by the local ethics committee and was according to the Declaration of Helsinki. Written and oral informed consent was obtained from each patient. Five male and one female patient (mean age: 50.0±10.9, range 38-66 years, all right-handed), diagnosed with AUD for several years (mean 16.8±9.4 years) were included after completed alcohol withdrawal. They were recruited at the Psychiatric Hospital of the University of Munich, center for addiction disorders, day hospital and inpatient ward, respectively. Exclusion criteria were history of severe neurologic (e.g., stroke, epilepsy) or internal disease (e.g., cancer, metabolic disorders), metal implants or current skin diseases. All patients were randomly assigned to two groups, receiving 20 respectively 10 gamma tACS sessions within two weeks, either for 10 min twice daily (group 1) or 20 min once per day (group 2) (see CONSORT Flowchart in Fig. 1).

Comment [DN2]: Here need of the study can be written

Comment [DN3]: Add objectives of the study before starting giving materials and methods.

Comment [DN4]: Mention the Research approach and design for the current study

Comment [DN5]: Elaborate How the samples were randomly assigned?

Comment [DN6]: Give clear instruction for the 20 sessions like; duration of each session, Number of sessions with type of intervention, pretesting done or not




Figure 1. Consort Flowchart.

2.2. Stimulation Procedures

For gamma tACS, a CE-certified neuroConn Eldith® DC-stimulator was used. Stimulation parameters were set to a current of 2 mA (amplitude -1 mA to +1 mA, peak-to-peak) at 40 Hz (0° phase shift, i.e., in-phase stimulation). In total, 48,000 cycles of tACS were applied per day over ten workdays sparing the weekend. Saline-soaked sponge electrodes (35 cm²) were placed over left and right dorsolateral prefrontal cortices (DLPFC), i.e., F3 and F4, according to the international 10-20-EEG system, and fixed with rubber bands to the skull. Stimulations were performed in the morning (20 min), respectively in the morning and within an interval of three hours (2x10 min).

2.3. Rating Instruments

Patients were assessed with objective and subjective rating instruments at three time points: At baseline (BL), after 5th stimulation (D5), and after the 10th stimulation (D10). Patients were assessed at all three time points by:

- a) Alcohol Craving Questionnaire-short form-revised (ACQ-SF-R) (Singleton et al., 1995): This specific rating instrument for assessment of craving consists in 12 questions with proposed answers scoring from 1 to 7. Sum score of the 12 items indicates craving severity, subgroups indicate the four factors 'compulsivity, expectancy, purposefulness, emotionality'.
- b) Regensburg Word Fluency Test (RWT) (Aschenbrenner et al., 2000): This German language test for semantic word fluency, attention, and cognition requires the participant to cite as many words with a given capital letter as possible within one minute. The number of correct words is summarized.
- c) Trail Making Test A and B (TMT-A/B) (Reitan, 1958): This test for attention and cognition is widely used and comprises two parts: in part A, participants must link numbers 1-25 as quick as possible. In part B, a number-letter sequence must be linked. Outcome parameters are time and errors.
- d) Positive and Negative Affect Schedule (PANAS) (Watson et al., 1988): This scale for assessing a subject's emotional state uses 20 adjectives with a 5-point Likert scale for refusal or agreement. Mean values indicate a mood profile over the past week.
- e) Clinical Global Impression (CGI) (Guy, 1976): This two-part scale focuses on illness severity and clinical improvement. Although being a raw scale, it is widely used and helps to depict clinical courses. In this study, only the first part was used.
- f) Computer-based n-back test (3-back test), calculated with a d-prime value (sensitive index d') (Papazova et al., 2018): On a standard computer screen, participants are presented with a letter from an 8-letter set, randomly selected from the alphabet [A to Z] for 500 ms in a pseudo-randomized order. In three consecutive experimental blocks with increasing cognitive load, participants must press a button when the presented letter matched the letter one (1-back, 121 trials), two (2-back, 122 trials) or three (3-back, 123 trials) items before.

At the end of each week of stimulation, patients filled-in the Comfort Rating Questionnaire (CRQ) (Palm et al., 2014) for assessing side effects of the stimulation. This Likert-scaled questionnaire assesses side effects of electrical stimulation during and after stimulation, as well as general comfort, and light flashes (phosphenes) and sleep disturbances as a dichotomous question. At baseline (BL), the following tests were performed additionally:

- a) Multiple-choice vocabulary intelligence test (MWT-B, Mehrfachwahl-Wortschatz-Intelligenztest) (Lehrl et al., 1995): This test measures semantic intelligence by presenting 37 lines with 5 words each in German language. Only one word per line is correct and needs to be recognized. Sum scores point to different intelligence levels.
- b) Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al., 1993): The Audit is one of the most popular screening instruments of Alcohol dependency and has been translated in different languages. Questions sum up to a score between 0 and 40 points, indicating severity of alcohol abuse. Cutoff for critical use is ≥ 8 points.
- c) Fagerström test for nicotine dependence (FTND) (Heather et al., 1991): FTND is a standard rating instrument to assess the severity of nicotine dependence. To score the FTND, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.

- d) Edinburgh Handedness Test (EHT) (Oldfield, 1971): This 14-item questionnaire delivers a percentage value between -100 and +100 for indicating left- respectively right-handed persons and their dominant hemispheres.

Craving for alcohol was assessed at each day of stimulation with a custom-made visual analogue scale (VAS), consisting of smiley icons that were collated to integral numbers between 1 (no craving at all) and 10 (maximum craving).

2.4. Statistics

Due to the small number of participants in this pilot study, no analysis tools to proof significance levels were used. For the computer-based n-back test (3-back test), d-prime value (sensitive index d') was calculated with a standard scheme (Haatveit et al., 2010).

3. RESULTS

3.1. Demographic Results

Five patients completed the study; one male patient (group 1) withdrew his consent for personal reasons after 8th stimulation. His results were included in analysis up to D5. Patients were all right-handed. Further clinical characteristics, i.e., duration of illness, number of hospitalisations and other are shown in Table 1. Clinical outcomes, craving measures, and cognitive outcomes are shown in Fig. 2a, 2b, and Fig. 3a, 3b. Most patients received anti-craving drugs (i.e., acamprosate in several cases; Table 1) which were kept stable for at least one week before enrolment and throughout stimulation series.

Figure 2a. Clinical Results. Performance (y-axis: score, x-axis: Rating Scales) in the Trail Making Test A and B (TMT-A/B) and Regensburg Word Fluency Test (RWT) at Baseline (BL), day 5 (D5), and day 10 (D10). Clinical scores are given in mean values and standard deviation.




Figure 2b. Clinical Results. Performance (y-axis: score, x-axis: Rating Scales) in the d-prime value (n-back) and the Alcohol Craving Questionnaire-short form-revised (ACQ-SF-R) at Baseline (BL), day 5 (D5), and day 10 (D10). Clinical scores are given in mean values and standard deviation.




Figure 3a. Craving for alcohol Visual analogue scale (VAS; score 1-10), daily measure during course of treatment for group 1 (2x10 min/day).




Figure 3b. Craving for alcohol Visual analogue scale (VAS; score 1-10), daily measure during course of treatment for group 2 (1x20 min/day).

Baseline measurements (MWT-B, AUDIT, and FTND) showed no obvious differences between both groups. The MWT-B was 30.2 ± 3.2 points, the FTND was 2.3 ± 1.7 points (three of five were smokers). The AUDIT score, reflecting drinking behaviour and amount, was 32.3 ± 3.9 points. Patients' history of previous inpatient treatment ranged from 2 to 20 periods.

3.2. Clinical Results

At baseline, group 1 (2x10 min/day) presented a mean ACQ-SF-R score of 4.4 ± 0.8 , and RWT with 42.3 ± 18.8 words. TMT-A was performed in 30.5 ± 6.0 sec, and TMT-B in 60.6 ± 12.8 sec respectively. The Positive Affect Schedule showed 2.8 ± 0.4 , and 2.6 ± 1.1 respectively in the Negative Affect Score. CGI was 4.3 ± 0.6 . The baseline d-prime of the virtual n-back was 2.3 ± 0.7 .

After the 5th stimulation, group 1 showed a mean ACQ-SF-R Score with 3.6 ± 0.4 , and RWT with 51.7 ± 20.1 words. TMT-A was performed in 29.4 ± 6.4 sec, and TMT-B in 53.3 ± 10.4 sec respectively. The Positive Affect Schedule showed 3.1 ± 0.6 , and 1.9 ± 0.7 respectively in the Negative Affect Score. CGI was 4.0 ± 0.0 . The average d-prime of the virtual n-back was 2.6 ± 0.3 .

After the 10th stimulation, group 1 showed a mean ACQ-SF-R Score of 2.5 ± 0.7 , and RWT with 61.5 ± 36.1 words. TMT-A was performed in 27.1 ± 8.4 sec, and TMT-B in 51.8 ± 3.6 sec respectively. The Positive Affect Schedule showed 3.0 ± 1.3 , and 2.1 ± 0.7 respectively in the Negative Affect Score. CGI was 2.5 ± 0.7 . The d-prime of the virtual n-back was 3.0 ± 0.4 . Craving for alcohol with a visual analogue scale (VAS) showed scores between 1 and 5 at start of treatment, and an improvement to a score of 2 (2 remaining patients in group 1) at the end of treatment.

Group 2 (1x20 min/day) presented a mean ACQ-SF-R Score of 2.9 ± 0.8 at baseline, and RWT with 39.0 ± 19.9 words. TMT-A was performed in 31.9 ± 7.1 sec, and TMT-B in 80.2 ± 41.9 sec respectively. The Positive Affect Schedule showed 2.8 ± 0.7 , the Negative Affect Score showed 2.5 ± 0.8 . CGI was 4.3 ± 1.2 . The baseline d-prime of the virtual n-back was 2.2 ± 0.6 .

At D5, group 2 presented a mean ACQ-SF-R Score of 2.9 ± 1.0 , and RWT with 47.3 ± 29.5 words. TMT-A was performed in 29.8 ± 7.3 sec, and TMT-B in 72.5 ± 42.1 sec respectively. The Positive Affect Schedule showed 2.9 ± 0.7 , the Negative Affect Score showed 1.9 ± 0.5 . CGI was 4.0 ± 1.0 . The average d-prime of the virtual n-back was 2.1 ± 1.3 .

At D10, group 2 presented a mean ACQ-SF-R Score of 2.0 ± 0.7 , and RWT with 58.7 ± 24.2 words. TMT-A was performed in 26.7 ± 10.2 sec, and TMT-B in 54.3 ± 27.9 sec respectively. The Positive Affect Schedule showed 3.9 ± 0.4 , the Negative Affect Score showed 1.2 ± 0.1 . CGI was 2.3 ± 0.6 . The d-prime of the virtual n-back was 2.4 ± 0.7 .

In group 2, initial VAS scores were on a lower level (3 points) compared to group 1 and improved to 2 respectively 1 point.

3.3. Safety and Side Effects

Gamma tACS was safe and well tolerated. This overall impression was supported by the CRQ scores after the 5th (group 1: 30.0 ± 12.5 ; group 2: 31.0 ± 7.2) and the 10th stimulation (group 1: 19.0 ± 2.8 ; group 2: 23.0 ± 3.6). Five patients reported phosphenes during stimulation, but no one reported disturbed sleep. Two the smokers spontaneously reported less craving for tobacco.

4. DISCUSSION

This small open label pilot study provides first clinical evidence that gamma tACS may exert therapeutic effects in patients with AUD. Although improvement in the main outcome measures was observed in both groups, group 1 showed a slightly superior outcome on a descriptive level, however group 2 showed higher changes in the total scores. Theoretically, tACS for 10 min twice daily may represent a treatment protocol with effects distinct from those after a single 20 min stimulation per day as similarly shown in an early motor cortex tDCS study comparing different stimulation periods (Nitsche & Paulus, 2001; Fricke et al., 2011; Monte-Silva et al., 2013). For tDCS in AUD, Klauss et al. (Klauss et al., 2018) observed a reduction of craving through multiple sessions of tDCS stimulation. Analogously, repeated gamma tACS sessions seem to have a positive effect on AUD symptoms as well as cognitive measures. Such effects on cognition may be explained by modulation of prefrontal neural activity, as shown in a recent study for tACS in healthy volunteers (Zaehle et al., 2010). Similarly, tACS may drive synchronization of disturbed alpha activity of frontal and prefrontal brain regions, resulting in an improvement of processing complex tasks like TMT, RWT, or n-back test.

Finally, it should be mentioned that gamma tACS was well tolerated and there were no serious adverse effects.

Limitations of this pilot study are the small sample size and the lack of a control group. Therefore, deflecting a hypothesis from these results for building a randomized placebo-controlled trial could result in biased study design and power analysis (Albers & Lakens, 2018; Kraemer et al., 2006). Furthermore, our study does not allow to specifically attribute the observed changes to gamma tACS treatment. In addition, there might have been strong nonspecific effects of care and patients' expectations raised by the procedure of stimulation itself, which could have driven the results (Braga et al., 2021).

Most patients were treated with anti-craving drugs like acamprosate, which could have influenced craving measures even when medication was kept stable one week before and throughout the treatment.

Comment [DN7]:

Comment [DN8]: This can be added in a separate heading as recommendation for further research

5. CONCLUSION

In sum, treatment with 40 Hz tACS treatment was safe and showed preliminary efficacy in this small open label pilot study with six patients suffering from AUD.

Gamma tACS is a novel and promising NIBS technique in AUD and merits further investigation as it is low cost, easy to use and nearly free of side effects. Randomized controlled trials including neurobiological measures are needed for assessing its efficacy and to develop a deeper mechanistic understanding of gamma tACS action.

CONSENT

All authors declare that written and oral informed consent was obtained from all patients.

Comment [DN9]: Conflict of Interest also be added

ETHICAL APPROVAL

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Ludwig-Maximilian University, Munich, Germany (protocol code 603-16; date of approval: 14 Nov 2016).

REFERENCES

1. Albers, C., Lakens, D. When power analyses based on pilot data are biased: inaccurate effect size estimators and follow-up bias. *J. Exp. Soc. Psychol.* 2018; 74, 187–195.
2. Ahveninen, J.; Escera, C.; Polo, M.D.; Grau, C.; Jääskeläinen, I.P. Acute and Chronic Effects of Alcohol on Preattentive Auditory Processing as Reflected by Mismatch Negativity. *Audiol. Neurootol.* 2000, 5, 303–311. [CrossRef]
3. Alexander, M. L., Alagapan, S., Lugo, C. E., Mellin, J. M., Lustenberger, C., Rubino, D. R., & Fröhlich, F. (2019). Double-blind, randomized pilot clinical trial targeting alpha oscillations with transcranial alternating current stimulation (tACS) for the treatment of major depressive disorder (MDD). *Translational Psychiatry*, 9(1), 106. <https://doi.org/10.1038/s41398-019-0439-0>
4. Ambrus GG, Pisoni A, Primaßin A, Turi Z, Paulus W, Antal A. Bi-frontal transcranial alternating current stimulation in the ripple range reduced overnight forgetting. *Front Cell Neurosci.* 2015 Sep 24;9:374. doi: 10.3389/fncel.2015.00374. PMID: 26441544; PMCID: PMC4585169.
5. Antal A, Paulus W. Transcranial alternating current stimulation (tACS). *Front Hum Neurosci.* 2013 Jun 28;7:317. doi: 10.3389/fnhum.2013.00317. PMID: 23825454; PMCID: PMC3695369.
6. Aschenbrenner S, Tucher O, Lange KW, Der Regensburger Wortflüssigkeits-Test. Handanweisung. Göttingen: Hogrefe, 2000.
7. Bernardin, F., Maheut-Bosser, A., & Paille, F. (2014). Cognitive Impairments in Alcohol-Dependent Subjects. *Frontiers in Psychiatry*, 5. <https://doi.org/10.3389/fpsy.2014.00078>
8. Boggio, P. S., Sultani, N., Fecteau, S., Merabet, L., Mecca, T., Pascual-Leone, A., ... Fregni, F. (2008). Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study. *Drug and Alcohol Dependence*, 92(1–3), 55–60. <https://doi.org/10.1016/j.drugalcdep.2007.06.011>
9. Braga, M.; Barbiani, D.; Emadi Andani, M.; Villa-Sánchez, B.; Tinazzi, M.; Fiorio, M. The Role of Expectation and Beliefs on the Effects of Non-Invasive Brain Stimulation. *Brain Sci.* 2021, 11, 1526. <https://doi.org/10.3390/brainsci11111526>
10. Chaieb L, Antal A, Paulus W. Transcranial alternating current stimulation in the low kHz range increases motor cortex excitability. *Restor Neurol Neurosci.* 2011;29(3):167-75. doi: 10.3233/RNN-2011-0589. PMID: 21586823.
11. da Silva, M. C., Conti, C. L., Klauss, J., Alves, L. G., do Nascimento Cavalcante, H. M., Fregni, F., ... Nakamura-Palacios, E. M. (2013). Behavioral effects of transcranial Direct Current Stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol

- dependence. *Journal of Physiology-Paris*, 107(6), 493–502. <https://doi.org/10.1016/j.jphysparis.2013.07.003>
12. Daughters SB, Yi JY, Phillips RD, Carelli RM, Fröhlich F. Alpha-tACS effect on inhibitory control and feasibility of administration in community outpatient substance use treatment. *Drug Alcohol Depend*. 2020 Jun 18;213:108132. doi: 10.1016/j.drugalcdep.2020.108132. Epub ahead of print. PMID: 32593154; PMCID: PMC8815795.
 13. Elyamany, O., Leicht, G., Herrmann, C.S. et al. Transcranial alternating current stimulation (tACS): from basic mechanisms towards first applications in psychiatry. *Eur Arch Psychiatry Clin Neurosci* 271, 135–156 (2021). <https://doi.org/10.1007/s00406-020-01209-9>
 14. Fitzgerald PJ, Watson BO. Gamma oscillations as a biomarker for major depression: an emerging topic. *Transl Psychiatry*. 2018 Sep 4;8(1):177. doi: 10.1038/s41398-018-0239-y. PMID: 30181587; PMCID: PMC6123432.
 15. Fricke K, Seeber AA, Thirugnanasambandam N, Paulus W, Nitsche MA, Rothwell JC. Time course of the induction of homeostatic plasticity generated by repeated transcranial direct current stimulation of the human motor cortex. *J Neurophysiol*. 2011 Mar;105(3):1141-9. doi: 10.1152/jn.00608.2009. Epub 2010 Dec 22. PMID: 21177994.
 16. Global status report on alcohol and health, 2014. (2014). <http://site.ebrary.com/id/10931311>
 17. Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., ... Hasin, D. S. (2015). Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA Psychiatry*, 72(8), 757. <https://doi.org/10.1001/jamapsychiatry.2015.0584>
 18. Grant, B. F., & Harford, T. C. (1995). Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. *Drug and Alcohol Dependence*, 39(3), 197–206. [https://doi.org/10.1016/0376-8716\(95\)01160-4](https://doi.org/10.1016/0376-8716(95)01160-4)
 19. Guy W. *Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology—Revised*. Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs. 1976: 218-222
 20. Haatveit, B. C., Sundet, K., Hugdahl, K., Ueland, T., Melle, I., & Andreassen, O. A. (2010). The validity of d prime as a working memory index: Results from the “Bergen n-back task”. *Journal of Clinical and Experimental Neuropsychology*, 32(8), 871–880. <https://doi.org/10.1080/13803391003596421>
 21. Haller N, Senner F, Brunoni AR, Padberg F, Palm U. Gamma transcranial alternating current stimulation improves mood and cognition in patients with major depression. *J Psychiatr Res*. 2020 Nov;130:31-34. doi: 10.1016/j.jpsychires.2020.07.009. Epub 2020 Jul 29. PMID: 32771678.
 22. Haller N, Hasan A, Padberg F, Brunelin J, da Costa Lane Valiengo L, Palm U. Gamma transcranial alternating current stimulation in patients with negative symptoms in schizophrenia: A case series. *Neurophysiol Clin*. 2020 Sep;50(4):301-304. doi: 10.1016/j.neucli.2020.06.004. Epub 2020 Jul 4. PMID: 32631667.
 23. Harada T, Hara M, Matsushita K, Kawakami K, Kawakami K, Anan M, Sugata H. Off-line effects of alpha-frequency transcranial alternating current stimulation on a visuomotor learning task. *Brain Behav*. 2020 Sep;10(9):e01754. doi: 10.1002/brb3.1754. Epub 2020 Jul 27. PMID: 33460319; PMCID: PMC7507357.
 24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict* 1991, 86:1119-27.
 25. Jafari E, Alizadehgoradel J, Pourmohseni Koluri F, Nikoozadehkordmirza E, Refahi M, Taherifard M, Nejati V, Hallajian AH, Ghanavati E, Vicario CM, Nitsche MA, Salehinejad MA. Intensified electrical stimulation targeting lateral and medial prefrontal cortices for the treatment of social anxiety disorder: A randomized, double-blind, parallel-group, dose-comparison study. *Brain Stimul*. 2021 Jul-Aug;14(4):974-986. doi: 10.1016/j.brs.2021.06.005. Epub 2021 Jun 22. PMID: 34167918.
 26. Kasten FH, Dowsett J, Herrmann CS. Sustained Aftereffect of α -tACS Lasts Up to 70 min after Stimulation. *Front Hum Neurosci*. 2016 May 25;10:245. doi: 10.3389/fnhum.2016.00245. PMID: 27252642; PMCID: PMC4879138.
 27. Klauss, J., Anders, Q. S., Felipe, L. V., Nitsche, M. A., & Nakamura-Palacios, E. M. (2018). Multiple Sessions of Transcranial Direct Current Stimulation (tDCS) Reduced Craving and Relapses for Alcohol Use: A Randomized Placebo-Controlled Trial in Alcohol Use Disorder. *Frontiers in Pharmacology*, 9, 716. <https://doi.org/10.3389/fphar.2018.00716>

28. Klink K, Paßmann S, Kasten FH, Peter J. The Modulation of Cognitive Performance with Transcranial Alternating Current Stimulation: A Systematic Review of Frequency-Specific Effects. *Brain Sci* 2020;10: 932.
29. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. *Arch Gen Psychiatry*. 2006 May;63(5):484-9. doi: 10.1001/archpsyc.63.5.484. PMID: 16651505.
30. Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. *Nat Rev Neurosci*. 2009 Feb;10(2):126-40. doi: 10.1038/nrn2572. PMID: 19153576; PMCID: PMC2664745.
31. Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). *Clin Neurophysiol* 2017;128: 56-92.
32. Lehl S, Triebig G, Fischer B. Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. *Acta Neurologica Scandinavica*, 1995, 91(5): 335-345.
33. Liang, J., & Olsen, R. W. (2014). Alcohol use disorders and current pharmacological therapies: The role of GABAA receptors. *Acta Pharmacologica Sinica*, 35(8), 981–993. <https://doi.org/10.1038/aps.2014.50>
34. McKim TH, Dove SJ, Robinson DL, Fröhlich F, Boettiger CA. Addiction history moderates the effect of prefrontal 10-Hz transcranial alternating current stimulation on habitual action selection. *J Neurophysiol*. 2021 Mar 1;125(3):768-780. doi: 10.1152/jn.00180.2020. Epub 2020 Dec 23. PMID: 33356905; PMCID: PMC7988748.
35. Mellin JM, Alagapan S, Lustenberger C, Lugo CE, Alexander ML, Gilmore JH, Jarskog LF, Fröhlich F. Randomized trial of transcranial alternating current stimulation for treatment of auditory hallucinations in schizophrenia. *Eur Psychiatry*. 2018 Jun;51:25-33. doi: 10.1016/j.eurpsy.2018.01.004. Epub 2018 Mar 11. PMID: 29533819; PMCID: PMC5994368.
36. Moirand R, Imbert L, Haesebaert F, Chesnoy G, Bediou B, Poulet E, Brunelin J. Ten Sessions of 30 Min tDCS over 5 Days to Achieve Remission in Depression: A Randomized Pilot Study. *J Clin Med*. 2022 Jan 31;11(3):782. doi: 10.3390/jcm11030782. PMID: 35160235; PMCID: PMC8836436.
37. Monte-Silva K, Kuo MF, Hessenthaler S, Fresnoza S, Liebetanz D, Paulus W, Nitsche MA. Induction of late LTP-like plasticity in the human motor cortex by repeated non-invasive brain stimulation. *Brain Stimul*. 2013 May;6(3):424-32. doi: 10.1016/j.brs.2012.04.011. Epub 2012 Jun 2. PMID: 22695026.
38. Mostafavi SA, Khaleghi A, Mohammadi MR. Noninvasive brain stimulation in alcohol craving: A systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2020 Jul 13;101:109938. doi: 10.1016/j.pnpbp.2020.109938. Epub 2020 Mar 29. PMID: 32234509.
39. Nitsche, M. A., & Paulus, W. (2001). Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. *Neurology*, 57(10), 1899–1901. <https://doi.org/10.1212/WNL.57.10.1899>
40. Oldfield, R. The assessment and analysis of handedness: The Edinburgh inventory. *Neuropsychologia*. 1971; 9(1): 97-113.
41. Padmanabhapillai, A.; Tang, Y.; Ranganathan, M.; Rangaswamy, M.; Jones, K.A.; Chorlian, D.B.; Kamarajan, C.; Stimus, A.; Kuperman, S.; Rohrbaugh, J.; et al. Evoked Gamma Band Response in Male Adolescent Subjects at High Risk for Alcoholism during a Visual Oddball Task. *Int. J. Psychophysiol*. 2006, 62, 262–271.
42. Palm U, Feichtner KB, Hasan A, Gauglitz G, Langguth B, Nitsche MA, Keeser D, Padberg F. The role of contact media at the skin-electrode interface during transcranial direct current stimulation (tDCS). *Brain Stimul*. 2014 Sep-Oct;7(5):762-4. doi: 10.1016/j.brs.2014.06.006. Epub 2014 Jun 20. PMID: 25018056.
43. Palm U, Baumgartner C, Hoffmann L, Padberg F, Hasan A, Strube W, Papazova I. Single session gamma transcranial alternating stimulation does not modulate working memory in depressed patients and healthy controls. *Neurophysiologie Clinique*, 2022, <https://doi.org/10.1016/j.neucli.2022.03.002>.
44. Papazova I, Strube W, Becker B, Henning B, Schwippel T, Fallgatter AJ, Padberg F, Palm U, Falkai P, Plewnia C, Hasan A. Improving working memory in schizophrenia: Effects of 1 mA and 2 mA transcranial direct current stimulation to the left DLPFC. *Schizophrenia Research*, 2018, 202: 203-209. <https://doi.org/10.1016/j.schres.2018.06.032>.
45. Porjesz, B.; Begleiter, H. Alcoholism and Human Electrophysiology. *Alcohol Res. Health* 2003, 27, 153–160.
46. Ramlakhan, J.U.; Ma, M.; Zomorodi, R.; Blumberger, D.M.; Noda, Y.; Barr, M.S. The Role of Gamma Oscillations in the Pathophysiology of Substance Use Disorders. *J. Pers. Med*. 2021, 11, 17. <https://dx.doi.org/10.3390/jpm11010017>

47. Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain Damage. *Perceptual and Motor Skills*. 1958;8(3):271-276. doi:10.2466/pms.1958.8.3.271
48. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. *Addiction* 1993, 88(6): 791-804.
49. Singleton EG, Tiffany ST, Henningfield JE. Development and validation of a new questionnaire to assess craving for alcohol Problems. *Probl Drug Depend* 1995, 2: 289.
50. Tavakoli AV, Yun K. Transcranial alternating current stimulation (tACS) mechanisms and protocols. *Front Cell Neurosci* 2017;11: 214
51. Vosskuhl J, Strüber D, Herrmann CS. Non-invasive Brain Stimulation: A Paradigm Shift in Understanding Brain Oscillations. *Front Hum Neurosci* 2018;12: 211.
52. Wach C, Krause V, Moliadze V, Paulus W, Schnitzler A, Pollok B. The effect of 10 Hz transcranial alternating current stimulation (tACS) on corticomuscular coherence. *Front Hum Neurosci*. 2013 Aug 29;7:511. doi: 10.3389/fnhum.2013.00511. PMID: 24009573; PMCID: PMC3756226.
53. Wang L, Nitsche MA, Zschorlich VR, Liu H, Kong Z, Qi F. 20 Hz Transcranial Alternating Current Stimulation Inhibits Observation-Execution-Related Motor Cortex Excitability. *J Pers Med*. 2021 Sep 29;11(10):979. doi: 10.3390/jpm11100979. PMID: 34683120; PMCID: PMC8541383.
54. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Personality Soc Psychology*. 1988, 54(6): 1063-1070.
55. Zaehle, T., Rach, S., & Herrmann, C. S. (2010). Transcranial Alternating Current Stimulation Enhances Individual Alpha Activity in Human EEG. *PLoS ONE*, 5(11), e13766. <https://doi.org/10.1371/journal.pone.0013766>

<i>Patient number</i>	<i>gender</i>	<i>age</i>	<i>age of onset</i>	<i>duration of illness</i>	<i>Concomitant medication</i>	<i>number of</i>	<i>Total duration of</i>	<i>course of illness</i>	<i>EHT</i>	<i>FTND</i>	<i>MWT-B</i>	
				(months)		<i>hospitalisations</i>	<i>hospitalisations (weeks)</i>		%			
Group 1	1	m	52	44	96	oxazepam 40mg mirtazapine 7.5mg	3	6	episodic	100	3	28
	2	m	42	34	96	quetiapine 25mg	20	40	episodic	100	0	35
	3	m	40	23	17	acamprosate 666mg	2	4	continuous	71.4	4	27
Group 2	4	m	66	30	360	acamprosate 666mg	6	78	episodic	100	0	34
	5	f	38	23	180	acamprosate 666mg naltrexone 50mg	2	6	continuous	100	3	30
	6	m	62	45	17	acamprosate 666mg	4	50	episodic	100	4	27

Table 1. Clinical and demographic characteristics at baseline. EHT = Edinburgh Handedness Test; FTND = Fagerström Test for Nicotine Dependence; MWT-B = multiple-choice vocabulary intelligence test

